ONCE / Spark Therapeutics, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

ONCE / Spark Therapeutics, Inc. / Partner Fund Management, L.P. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Spark Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 84652J103 (CUSIP Number) December 31, 2019 Date of Event Which Requi

ONCE / Spark Therapeutics, Inc. 15-12B - - FORM 15-12B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36819 Spark Therapeutics, Inc. (Exact name of registrant as specified in

Roche and Spark Therapeutics, Inc. announce closing of investigation and unconditional clearance by the FTC and expiration of Hart-Scott-Rodino waiting period for acquisition of Spark Therapeutics, Inc.

EX-99.(A)(5)(XXX) 2 dp117703ex99a5xxx.htm EXHIBIT (A)(5)(XXX) Exhibit (a)(5)(xxx) Media Release Roche and Spark Therapeutics, Inc. announce closing of investigation and unconditional clearance by the FTC and expiration of Hart-Scott-Rodino waiting period for acquisition of Spark Therapeutics, Inc. All antitrust approvals required to close the transaction received. Basel, 16 December 2019 - Roche (

ONCE / Spark Therapeutics, Inc. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 17, 2019 Registration No.

ONCE / Spark Therapeutics, Inc. SC 14D9/A - - AMENDMENT NO. 15 TO SCHEDULE 14D-9

Amendment No. 15 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 15) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001

ONCE / Spark Therapeutics, Inc. SC TO-T/A - - FORM SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 18) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Comm

Roche purchases shares in tender offer for Spark Therapeutics, Inc.

Exhibit (a)(5)(xxxi) Media Release Roche purchases shares in tender offer for Spark Therapeutics, Inc.

Bylaws of the Company (filed herewith).

EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF SPARK THERAPEUTICS, INC. * * * * * ARTICLE 1 OFFICES Section 1.01. Registered Office. The registered office of the Corporation shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 1.02. Other Offices. The Corporation may also have offices at such other places both within and without the State of Delaware as the Board

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 17, 2019 Spark Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36819 46-2654405 (State or other jurisdiction of incorporation) (Commiss

ONCE / Spark Therapeutics, Inc. SC 14D9/A - - AMENDMENT NO. 16 TO SCHEDULE 14D-9

Amendment No. 16 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 16) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001

ONCE / Spark Therapeutics, Inc. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 17, 2019 Registration No.

ONCE / Spark Therapeutics, Inc. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 17, 2019 Registration No.

Amended and Restated Certificate of Incorporation of the Company (filed herewith).

EX-3.1 2 d851263dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SPARK THERAPEUTICS, INC. FIRST: The name of the corporation is Spark Therapeutics, Inc. (the “Corporation”). SECOND: The address of its registered office in the State of Delaware is 251 Little Falls Drive, City of Wilmington, County of New Castle, Delaware 19808. The name of its registered agent at su

ONCE / Spark Therapeutics, Inc. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 17, 2019 Registration No.

ONCE / Spark Therapeutics, Inc. S-8 POS - - S-8 POS

S-8 POS As filed with the Securities and Exchange Commission on December 17, 2019 Registration No.

ONCE / Spark Therapeutics, Inc. SC TO-T/A - - FORM SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 17) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Comm

ONCE / Spark Therapeutics, Inc. SC 14D9/A - - AMENDMENT NO. 14 TO SCHEDULE 14D-9

Amendment No. 14 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 14) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001

Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority

Exhibit (a)(5)(xxix) Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority Basel, 16 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that the UK Competition and Markets Authority has unconditionally cleared Roche’s pending acquisition of Spark pursuant to its previously an

ONCE / Spark Therapeutics, Inc. SC TO-T/A - - FORM SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 16) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Comm

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. to December 16, 2019

Exhibit (a)(5)(xxviii) Media Release Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. to December 16, 2019 Basel, 9 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of

ONCE / Spark Therapeutics, Inc. SC TO-T/A - - FORM SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 15) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Comm

ONCE / Spark Therapeutics, Inc. SC 14D9/A - - AMENDMENT NO. 13 TO SCHEDULE 14D-9

SC 14D9/A 1 d837973dsc14d9a.htm AMENDMENT NO. 13 TO SCHEDULE 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 13) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Person(s) Filing Statement)

ONCE / Spark Therapeutics, Inc. SC TO-T/A - - FORM SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 14) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Comm

ONCE / Spark Therapeutics, Inc. SC 14D9/A - - AMENDMENT NO. 12 TO SCHEDULE 14D-9

Amendment No. 12 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 12) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

EX-99.(A)(5)(XXVII) 2 dp11621799a5xxvii.htm EXHIBIT (A)(5)(XXVII) Exhibit(a)(5)(xxvii) Media Release Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. Basel, 22 November 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previous

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36819 Spark Therapeutics, Inc.

ONCE / Spark Therapeutics, Inc. SC 14D9/A - - AMENDMENT NO. 11 TO SCHEDULE 14D-9

SC 14D9/A 1 d806266dsc14d9a.htm AMENDMENT NO. 11 TO SCHEDULE 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 11) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Person(s) Filing Statement)

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics,

Exhibit(a)(5)(xxvi) Media Release Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. Basel, 29 October 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares

ONCE / Spark Therapeutics, Inc. SC TO-T/A - - FORM SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 13) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Comm

ONCE / Spark Therapeutics, Inc. / Children's Hospital of Philadelphia Foundation - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 8)* Spark Therapeutics, Inc. (Name of Issuer) Common Stock. $0.001 par value (Title of Class of Securities) 84652J 103 (CUSIP Number) Jeffrey Kahn Executive Vice President and General Counsel The Children’s Hospital of Philadelphia Fo

ONCE / Spark Therapeutics, Inc. SC 14D9/A - - AMENDMENT NO. 10 TO SCHEDULE 14D-9

Amendment No. 10 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 10) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001

ONCE / Spark Therapeutics, Inc. SC TO-T/A - - FORM SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 12) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Comm

ONCE / Spark Therapeutics, Inc. SC 14D9/A - - AMENDMENT NO. 9 TO SCHEDULE 14D-9

Amendment No. 9 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 9) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001 PE

ONCE / Spark Therapeutics, Inc. SC TO-T/A - - FORM SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 11) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Comm

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

Exhibit(a)(5)(xxv) Media Release Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. Basel, 30 September 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2019 Spark Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36819 46-2654405 (State or other jurisdiction of incorporation) (Commiss

ONCE / Spark Therapeutics, Inc. SC 14D9/A - - AMENDMENT NO. 8 TO SCHEDULE 14D-9

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 8) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securit

ONCE / Spark Therapeutics, Inc. SC TO-T/A - - FORM SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 10) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Comm

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

EX-99.(A)(5)(XXIV) 2 dp111952ex99a5xxiv.htm EXHIBIT (A)(5)(XXIV) Exhibit Media Release Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. Basel, 3 September 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced t

ONCE / Spark Therapeutics, Inc. DEFA14A - - DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36819 Spark Therapeutics, Inc.

ONCE / Spark Therapeutics, Inc. SC 14D9/A - - AMENDMENT NO. 7 TO SCHEDULE 14D-9

Amendment No. 7 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 7) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001 PE

ONCE / Spark Therapeutics, Inc. SC TO-T/A - - FORM SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 9) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Commo

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

Exhibit (a)(5)(xxiii) Media Release Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. Basel, 31 July 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares o

ONCE / Spark Therapeutics, Inc. DEFA14A - - DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy

ONCE / Spark Therapeutics, Inc. DEF 14A - - DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant x Filed by a Party other than the Registrant: o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statemen

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2019 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (Com

ONCE / Spark Therapeutics, Inc. SC 14D9/A - - AMENDMENT NO. 6 TO SCHEDULE 14D-9

SC 14D9/A 1 d769927dsc14d9a.htm AMENDMENT NO. 6 TO SCHEDULE 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 6) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Person(s) Filing Statement) C

Amendment NO.1 to Agreement and Plan of Merger

Exhibit (d)(3) Amendment NO.1 to Agreement and Plan of Merger This Amendment NO.1 to Agreement and Plan of Merger (this “Amendment”) is entered into as of July 5, 2019 by and among Roche Holdings, Inc., a Delaware corporation (“Parent”), 022019 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Spark Therapeutics, Inc., a Delaware corporatio

To: Spark employees

Exhibit (a)(5)(xxii) To: Spark employees Dear all: It was my pleasure to meet with many of you in Philadelphia earlier this year and to share my excitement about the expected acquisition of Spark by Roche.

ONCE / Spark Therapeutics, Inc. SC TO-T/A - - FORM SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 8) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Commo

ONCE / Spark Therapeutics, Inc. SC 14D9/A - - AMENDMENT NO. 5 TO SCHEDULE 14D-9

Amendment No. 5 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 5) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001 PE

SPARK Q&A REGARDING FTC’S SECOND REQUEST

EX-99.(A)(5)(XX) 2 dp108339exa5xx.htm EXHIBIT (A)(5)(XX) Exhibit (a)(5)(xx) SPARK Q&A REGARDING FTC’S SECOND REQUEST 1. What is the purpose of the FTC (Federal Trade Commission) second request? A second request provides the FTC additional time to complete its current review and allows the FTC to receive additional documents and data to assist in conducting the review. The issuance of a second requ

ONCE / Spark Therapeutics, Inc. SC TO-T/A - - FORM SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 7) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Commo

Media Release

EX-99.(A)(5)(XXI) 3 dp108339exa5xxi.htm EXHIBIT (A)(5)(XXI) Exhibit (a)(5)(xxi) Media Release Roche and Spark Therapeutics, Inc. receive Request for Additional Information from FTC under Hart-Scott-Rodino Act and announce extension of tender offer for shares of Spark Therapeutics, Inc. Basel, 10 June 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) to

ONCE / Spark Therapeutics, Inc. SC 14D9/A AMENDMENT NO. 4 TO SCHEDULE 14D-9

Amendment No. 4 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 4) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001 PE

Roche and Spark Therapeutics, Inc. announce expected refiling date of Premerger Notification and Report Forms under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.

Exhibit (a)(5)(xix) Media Release Roche and Spark Therapeutics, Inc. announce expected refiling date of Premerger Notification and Report Forms under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc. · Parties elect to refile Premerger Notification and Report Forms on or about 23 May 2019 to provide the government with additional time to complete its current review B

ONCE / Spark Therapeutics, Inc. SC TO-T/A FORM SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 6) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Commo

Consulting Agreement between the Registrant and John P. Furey

Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”), made this 12th day of November, 2018, is entered into by Spark Therapeutics, Inc., a Delaware corporation with an address of 3737 Market Street, Suite 1300, Philadelphia, Pennsylvania 19104 (the “Company”), and John P. Furey an individual residing at 446 Boxwood Road, Bryn Mawr, PA 19010 (the “Consultant”). INTRODUCTION

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36819 Spark Therapeutics, Inc.

ONCE / Spark Therapeutics, Inc. / JP Morgan Chase & Co - NONE Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* Spark Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 84652J103 (CUSIP Number) April 30, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d

ONCE / Spark Therapeutics, Inc. 10-K/A Annual Report 10-K/A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K/A (Amendment No.

ONCE / Spark Therapeutics, Inc. SC 14D9/A AMENDMENT NO. 3 TO SCHEDULE 14D-9

Amendment No. 3 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 3) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001 PE

IN THE UNITED STATES DISTRICT COURT FOR NORTHERN, EAST ILLINOIS

Exhibit (a)(5)(xvii) IN THE UNITED STATES DISTRICT COURT FOR NORTHERN, EAST ILLINOIS CALVIN A.

SPARK Q&A REGARDING WITHDRAWAL AND REFILING NOTIFICATION

EX-99.(A)(5)(XVIII) 4 dp105565exa5xviii.htm EXHIBIT 99.(A)(5)(XVIII) Exhibit (a)(5)(xviii) SPARK Q&A REGARDING WITHDRAWAL AND REFILING NOTIFICATION 1. What is the purpose of the FTC (Federal Trade Commission) withdraw and refile notification? In order to provide the FTC with additional time to complete its current review, the parties have elected to withdraw and refile the notification form with t

Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.

EX-99.(A)(5)(XVI) 2 dp105565exa5xvi.htm EXHIBIT 99.(A)(5)(XVI) Exhibit (a)(5)(xvi) Media Release Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc. · Withdrawing and refiling the Premerger Notification and Report Form provides additional time for governm

ONCE / Spark Therapeutics, Inc. SC TO-T/A FORM SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Commo

ONCE / Spark Therapeutics, Inc. FORM SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Commo

Withdrawal and Refiling

Exhibit (a)(5)(xv) Withdrawal and Refiling REGARDING WITHDRAWAL AND REFILING NOTIFICATION 1.

ONCE / Spark Therapeutics, Inc. AMENDMENT NO. 2 TO SCHEDULE 14D-9

Amendment No. 2 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 2) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001 PE

ONCE / Spark Therapeutics, Inc. FORM SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Commo

Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.

Exhibit (a)(5)(xiv) Media Release Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc. Basel, 03 April 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has withdrawn its Premerger No

COMPLAINT FOR VIOLATION OF THE SECURITIES EXCHANGE ACT OF 1934

Exhibit (a)(5)(xiii) UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - X ZARRIN GOMEZ, Plaintiff, CASE NO.

ONCE / Spark Therapeutics, Inc. AMENDMENT NO. 1 TO SCHEDULE 14D-9

Amendment No. 1 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.001 PE

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

Exhibit (a)(5)(xii) UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ARTHUR NEWMAN, on behalf of himself and all others similarly situated, Plaintiff, vs.

UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE

EX-99.(A)(5)(X) 2 dp103757exa5x.htm EXHIBIT (A)(5)(X) Exhibit (a)(5)(x) UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE ELAINE WANG, : : Plaintiff, : Case No. : JURY TRIAL DEMANDED v. : : SPARK THERAPEUTICS, INC., STEVEN : ALTSCHULER, LARS EKMAN, : KATHERINE HIGH, JEFFREY D. : MARAZZO, ANAND MEHRA, VIN : MILANO, ROBERT J. PEREZ, ELLIOT : SIGAL, and LOTA ZOTH, : : Defendants. : COMPLAINT FOR VIOL

ONCE / Spark Therapeutics, Inc. FORM SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Commo

UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE

Exhibit (a)(5)(xi) UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE MICHAEL KENT, Individually and On ) Behalf of All Others Similarly Situated, ) ) Plaintiff, ) Case No.

ONCE / Spark Therapeutics, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Spark Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 84652J103 (CUSIP Number) February 28, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

ONCE / Spark Therapeutics, Inc. FORM SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons—Offeror) Commo

Roche Press Release announcing the commencement of the Offer, dated as of March 7, 2019.

Exhibit (a)(5)(ix) Media Release Roche commences tender offer for all shares of Spark Therapeutics, Inc.

ONCE / Spark Therapeutics, Inc. SCHEDULE 14D-9

Schedule 14D-9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Confidentiality Agreement, dated as of October 9, 2018, between Roche Holdings, Inc. and Spark Therapeutics, Inc.

EX-99.(d)(2) Exhibit 99.(d)(2) MUTUAL NON-DISCLOSURE AGREEMENT THIS MUTUAL NON-DISCLOSURE AGREEMENT (this “Agreement”), entered into as of October 9, 2018 (the “Effective Date”), governs the disclosure of information by and between Spark Therapeutics, Inc., a Delaware corporation, having an address at 3737 Market Street, Suite 1300, Philadelphia, PA (“Spark”), and Roche Holdings Inc, a Delaware co

ONCE / Spark Therapeutics, Inc. SC TO-T

SC TO-T 1 d642137dsctot.htm SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Pers

Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

EX-99.A.1.V Exhibit (a)(1)(v) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Spark Therapeutics, Inc. at $114.50 Net per Share Pursuant to the Offer to Purchase Dated March 7, 2019 by 022019 Merger Subsidiary, Inc. a wholly owned subsidiary of Roche Holdings, Inc. THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, AT THE END OF THE DAY ON APRIL 3, 2

Letter of Transmittal (including Guidelines for Certification of Taxpayer Identification Number on IRS Form W-9).

EX-99.A.1.II 3 d642137dex99a1ii.htm EX-99.A.1.II Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of Spark Therapeutics, Inc. at $114.50 Net per Share Pursuant to the Offer to Purchase Dated March 7, 2019 by 022019 Merger Subsidiary, Inc. a wholly owned subsidiary of Roche Holdings, Inc. THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, AT THE E

Offer to Purchase, dated as of March 7, 2019.

EX-99.A.1.I Table of Contents Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Spark Therapeutics, Inc. at $114.50 Net Per Share by 022019 Merger Subsidiary, Inc. a wholly owned subsidiary of Roche Holdings, Inc. THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TIME, AT THE END OF THE DAY ON APRIL 3, 2019, UNLESS THE OFFER IS EXTENDED OR

Notice of Guaranteed Delivery.

EX-99.A.1.III 4 d642137dex99a1iii.htm EX-99.A.1.III Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of Spark Therapeutics, Inc. at $114.50 Net per Share Pursuant to the Offer to Purchase Dated March 7, 2019 by 022019 Merger Subsidiary, Inc. a wholly owned subsidiary of Roche Holdings, Inc. THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 12:00 MIDNIGHT, NEW YORK CITY TI

Summary Advertisement as published in the Wall Street Journal on March 7, 2019.

EX-99.A.1.VI Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely pursuant to the Offer to Purchase dated March 7, 2019 and the related Letter of Transmittal and any amendments or supplements thereto and is being made to all holders of Shares. The Offer is not being made to

Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

Exhibit (a)(1)(iv) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Spark Therapeutics, Inc.

ONCE / Spark Therapeutics, Inc. / Children's Hospital of Philadelphia Foundation - SC 13D/A Activist Investment

SC 13D/A 1 d716743dsc13da.htm SC 13D/A CUSIP No. 84652J 103 13D Page 1 of 5 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 7)* Spark Therapeutics, Inc. (Name of Issuer) Common Stock. $0.001 par value (Title of Class of Securities) 84652J 103 (CUSIP Number) Jeffrey Kahn Executive Vice

Amendment No. 1, dated October 1, 2018, to the Lease Agreement dated November 20, 2017 between the Registrant and Brandywine 3025 Market, LP

EX-10.41 2 exhibit1041-spark1stam.htm EXHIBIT 10.41 Tenant: Spark Therapeutics, Inc. Premises: 3025 Market St., Suites 016, 026, 200, 300 & 400 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (“Amendment”) is made and entered into as of October 1, 2018, by and between BRANDYWINE 3025 MARKET, LP, a Pennsylvania limited partnership (“Landlord”), and SPARK THERAPEUTICS, INC., a Delaware corpor

License Agreement Amendment dated March 10, 2016 (effective November 23, 2015) amending and superseding the License Agreement between the Company and the Children's Hospital of Philadelphia dated November 23, 2015

Exhibit 10.42 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AGREEMENT AMENDMENT This Amendment (the "Amendment"), with an effective date of November 23, 2015 (the "Effective Date") serves as a modification to the November 23, 2015 License Agreement made by and between Spark Therapeutics, Inc., a Delaware

Subsidiaries of the Registrant

Exhibit 21.1 The following is a list of subsidiaries of the Company as of December 31, 2018: Name Jurisdiction of Incorporation Spark Therapeutics, Inc. Delaware Spark Therapeutics International Holdings, Inc. Delaware Spark Therapeutics Ireland Limited Ireland Spark Therapeutics UK Limited England Spark Therapeutics Argentina Limited Argentina Spark Therapeutics Switzerland Limited Switzerland Sp

ONCE / Spark Therapeutics, Inc. 10-K (Annual Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36819 Spark Therapeutics, Inc.

ONCE / Spark Therapeutics, Inc.

February 27, 2019 United States Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street, NE Washington, DC 20549 Attention: Ibolya Ignat & Mary Mast Re: Spark Therapeutics, Inc.

Q&A provided to employees of Spark Therapeutics, Inc. on February 25, 2019 (incorporated by reference to the Company’s Solicitation/Recommendation Statement on Schedule 14D-9 filed on February 25, 2019).

SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 84652J103 (CUSIP Numbe

ONCE / Spark Therapeutics, Inc. SC14D9C

SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 84652J103 (CUSIP Numbe

Social media post by Jeffrey D. Marrazzo, the Company’s Chief Executive Officer, on www.twitter.com (incorporated by reference to the Company’s Solicitation/Recommendation Statement on Schedule 14D-9 filed on February 25, 2019).

EX-99.2 Exhibit 99.2 Jeff Marrazzo @jeffmarrazzo. 3mIt’s a great day for patients, genetic medicine and the city of Philadelphia. @Roche will help us accelerate the development of more #genetherapies for more patients with new diseases and further expedite @sparktx’s vision of a world where no life is limited by genetic disease. Spark Therapeutics @sparktx We’ve entered inot a definitive merger ag

Social media post by Spark Therapeutics, Inc. on www.twitter.com (incorporated by reference to the Company’s Solicitation/Recommendation Statement on Schedule 14D-9 filed on February 25, 2019).

EX-99.1 Exhibit 99.1 Spark Therapeutics @Sparktx 8m We’ve entered into a definitive merger agreement with @Roche to further our vision of a world where no life is limited by genetic disease. Read more: ir.sparktx.com/news-releases/...

1

Exhibit 99.2 Key Messages and Q&A: Roche / Spark Therapeutics transaction Date: 25th of February, 2019 Approved spokespeople: Roche Media Relations, Severin Schwan (top-tier) and James Sabry Key Messages Transformational potential for patients of gene therapy and what Roche can bring to Spark Therapeutics’ research: · We believe gene therapy has transformational potential for patients, both in mon

Media Release

Exhibit 99.1 Media Release Basel, 25 February 2019 Roche enters into definitive merger agreement to acquire Spark Therapeutics · Roche to acquire Spark Therapeutics for US$ 114.50 per share · Spark Therapeutics is a leader in discovering, developing and delivering gene therapies with one commercial asset and four programmes currently in clinical trials · Transaction expected to close in Q2, 2019 R

ONCE / Spark Therapeutics, Inc. FORM SC TO-C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 SPARK THERAPEUTICS, INC. (Name of Subject Company) 022019 MERGER SUBSIDIARY, INC. (Offeror) A Wholly Owned Subsidiary of ROCHE HOLDINGS, INC. (Parent of Offeror) (Names of Filing Persons – Offeror) Common Stock, Par Val

Email sent to Spark Therapeutics, Inc. employees from Jeffrey Marrazzo, CEO of Spark Therapeutics, Inc., dated February 25, 2019 (incorporated by reference to the Spark Therapeutics, Inc. Solicitation/Recommendation Statement on Form 14D-9 (File No. 005-88577) filed with the Commission on February 25, 2019).

SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 84652J103 (CUSIP Numbe

ONCE / Spark Therapeutics, Inc. SC14D9C

SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Spark Therapeutics, Inc. (Name of Subject Company) Spark Therapeutics, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 84652J103 (CUSIP Numbe

Amendment to Amended and Restated By-laws of Spark Therapeutics, Inc. dated February 22, 2019

EX-3.1 Exhibit 3.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED BY-LAWS OF SPARK THERAPEUTICS, INC. Article V of the Amended and Restated By-laws of Spark Therapeutics, Inc. is hereby amended by adding the following new Section 5.9: 5.9 Exclusive Jurisdiction of Delaware Courts for Certain Claims. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery

Agreement and Plan of Merger, dated as of February 22, 2019, among Spark Therapeutics, Inc., Roche Holdings, Inc. and 022019 Merger Subsidiary, Inc.

EX-2.1 Table of Contents Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among ROCHE HOLDINGS, INC., 022019 MERGER SUBSIDIARY, INC. and SPARK THERAPEUTICS, INC. Dated as of February 22, 2019 Table of Contents TABLE OF CONTENTS Page Article 1 DEFINITIONS 2 Section 1.1. Definitions 2 Article 2 THE OFFER 11 Section 2.1. Tender Offer 11 Section 2.2. Actions of Parent and Merger Sub 1

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2019 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation)

Spark Therapeutics Enters into Definitive Merger Agreement with Roche Roche to acquire Spark Therapeutics for $114.50 per share representing a total equity value of $4.8 billion Spark Therapeutics will continue its operations in Philadelphia as an in

EX-99.1 Exhibit 99.1 Spark Therapeutics Enters into Definitive Merger Agreement with Roche Roche to acquire Spark Therapeutics for $114.50 per share representing a total equity value of $4.8 billion Spark Therapeutics will continue its operations in Philadelphia as an independent company within the Roche Group Transaction expected to close in Q2, 2019 PHILADELPHIA, Feb. 25, 2019 (GLOBE NEWSWIRE)—

Spark Therapeutics Reports 2018 Financial Results and Recent Business Progress

EX-99.1 2 spark-exhibit991fullyear20.htm EXHIBIT 99.1 EARNINGS PRESS RELEASE Exhibit 99.1 Spark Therapeutics Reports 2018 Financial Results and Recent Business Progress PHILADELPHIA, Feb. 19, 2019 (GLOBE NEWSWIRE)- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate and finan

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2019 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (Commiss

ONCE / Spark Therapeutics, Inc.

February 19, 2019 United States Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street, NE Washington, DC 20549 Attention: Ibolya Ignat & Mary Mast Re: Spark Therapeutics, Inc.

ONCE / Spark Therapeutics, Inc. / Partner Fund Management, L.P. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Spark Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 84652J103 (CUSIP Number) December 31, 2018 Date of Event Which Requi

ONCE / Spark Therapeutics, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Spark Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 84652J103 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

ONCE / Spark Therapeutics, Inc. / VANGUARD GROUP INC Passive Investment

sparktherapeuticsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2 )* Name of issuer: Spark Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 84652J103 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropri

ONCE / Spark Therapeutics, Inc. / JP Morgan Chase & Co - NONE Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Spark Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 84652J103 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t

ONCE / Spark Therapeutics, Inc.

January 3, 2019 United States Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance 100 F Street, NE Washington, DC 20549 Attention: Ibolya Ignat & Mary Mast Re: Spark Therapeutics, Inc.

ONCE / Spark Therapeutics, Inc. S-8

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 46-2654405 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 3737 Market Street Suite 1300 Philadelphia, Pennsylvania 19104

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2019 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (Commissio

Corporate Overview January 2019 1 Investor communication only: Not for use in promotion Forward-looking statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, inc

jpm2019posteddeck Corporate Overview January 2019 1 Investor communication only: Not for use in promotion Forward-looking statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s product and product candidates, including LUXTURNA® (voretigene neparvovec-rzyl), SPK-7001, SPK-9001, SPK-3006, SPK-8011 and SPK-8016.

JOINT FILING AGREEMENT

EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Common Stock of Spark Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the

ONCE / Spark Therapeutics, Inc. / Partner Fund Management, L.P. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Spark Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 84652J103 (CUSIP Number) December 18, 2018 Date of Event Which Require

Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2018 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation)

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2018 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation)

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2018 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (Commissi

Spark Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Progress

EX-99.1 2 spark-exhibit991q32018.htm EXHIBIT 99.1 Exhibit 99.1 Spark Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Progress PHILADELPHIA, Nov. 6, 2018 (GLOBE NEWSWIRE)- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate and financial results f

ONCE / Spark Therapeutics, Inc. 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36819 Spark Therapeutics, Inc.

Cash Collateral Agreement, dated July 3, 2018, between the Registrant and Wells Fargo Bank, National Association

EXECUTION VERSION CASH COLLATERAL AGREEMENT This CASH COLLATERAL AGREEMENT (this “Agreement”), dated as of July 3, 2018, is entered into by and between SPARK THERAPEUTICS, INC.

Credit Agreement, dated July 3, 2018, between the Registrant and Wells Fargo Bank, National Association

EXECUTION VERSION CREDIT AGREEMENT Dated as of July 3, 2018 between SPARK THERAPEUTICS, INC.

Dedicated Manufacturing and Commercial Supply Agreement, dated August 3, 2018, between the Registrant and Brammer Bio MA, LLC

EXECUTION VERSION Confidential Materials omitted and filed separately with the Securities and Exchange Commission.

ONCE / Spark Therapeutics, Inc. 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36819 Spark Therapeutics, Inc.

Asset Purchase Agreement, dated April 30, 2018 between the Registrant and Jazz Pharmaceuticals Ireland Limited

EXECUTION VERSION ASSET PURCHASE AGREEMENT BY AND BETWEEN JAZZ PHARMACEUTICALS IRELAND LIMITED AND SPARK THERAPEUTICS, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2018 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (Commission

Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress As of July 13, 2018, preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A show:

Exhibit 99.1 Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress As of July 13, 2018, preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A show: • A 97-percent reduction in annualized bleeding rate (ABR) and 97-percent reduction in annualized infusion rate (AIR) across all 12 participants in the study • Evidence of stable, durable expre

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2018 Spark Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36819 46-2654405 (State or other jurisdiction of incorporation) (Commission F

Submission of Matters to a Vote of Security Holders

8-K 1 spark-2018annualmeeting.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2018 Spark Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36819 46-2654405 (State or other jurisd

ONCE / Spark Therapeutics, Inc. 8-K (Current Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2018 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (Commission F

ONCE / Spark Therapeutics, Inc. 8-K (Current Report)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2018 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (Commission Fi

Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress Achieved historic milestone with first patients treated with LUXTURNA™ (voretigene neparvovec-rzyl)

Exhibit 99.1 Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress Achieved historic milestone with first patients treated with LUXTURNA™ (voretigene neparvovec-rzyl) PHILADELPHIA, May 8, 2018 (GLOBE NEWSWIRE)- Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced to

Manufacture and Supply Agreement, dated February 16, 2018, between the Registrant and Pfizer

Execution Version Confidential Materials omitted and filed with the Securities and Exchange Commission.

ONCE / Spark Therapeutics, Inc. 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36819 Spark Therapeutics, Inc.

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2018 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (Commission

ONCE / Spark Therapeutics, Inc. DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant x Filed by a Party other than the Registrant: o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statemen

ONCE / Spark Therapeutics, Inc. DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant x Filed by a Party other than the Registrant: o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statemen

ONCE / Spark Therapeutics, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Spark Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 84652J103 (CUSIP Number) March 30, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

ONCE / Spark Therapeutics, Inc. / FEDERATED INVESTORS INC /PA/ Passive Investment

OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1*) SPARK THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 84652J103 (CUSIP Number) February 28, 2018 (Date of Event Which Requires Filing of t

ONCE / Spark Therapeutics, Inc. / Children's Hospital of Philadelphia Foundation - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 6)* Spark Therapeutics, Inc. (Name of Issuer) Common Stock. $0.001 par value (Title of Class of Securities) 84652J 103 (CUSIP Number) Jeffrey D. Kahn, Esq. Executive Vice President and General Counsel The Children’s Hospital of Philadelphia Fo

Amendment No. 2, dated November 6, 2017, to the License Agreement dated December 6, 2014 between the Registrant and Pfizer

CONFIDENTIAL EXECUTION VERSION November 6, 2017 Confidential Materials omitted and filed separately with the Securities and Exchange Commission.

Lease Agreement, dated as of November 20, 2017, between the Registrant and Brandywine 3025 Market, LP

Tenant: Spark Therapeutics, Inc. Brandywine Realty Trust Premises: 3025 Market St., Suites 016, 026, 200 & 300 LEASE THIS LEASE (“Lease”) is entered into as of November 20, 2017, between BRANDYWINE 3025 MARKET, LP, a Pennsylvania limited partnership (“Landlord”), and SPARK THERAPEUTICS, INC., a Delaware corporation (“Tenant”). In consideration of the mutual covenants stated below, and intending to

Supply Agreement, dated January 24, 2018, between the Registrant and Novartis Pharma AG

Confidential Materials omitted and filed separately with the Securities and Exchange Commission.

ONCE / Spark Therapeutics, Inc. 10-K (Annual Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36819 Spark Therapeutics, Inc.

Subsidiaries of the Registrant

Exhibit 21.1 The following is a list of subsidiaries of the Company as of December 31, 2017: Name Jurisdiction of Incorporation Spark Therapeutics, Inc. Delaware Spark Therapeutics International Holdings, Inc. Delaware Spark Therapeutics Ireland Limited Ireland Spark Therapeutics UK Limited England Spark Therapeutics Argentina Limited Argentina Spark Therapeutics Switzerland Limited Switzerland Sp

License and Commercialization Agreement dated January 24, 2018 between the Registrant and Novartis Pharma AG

Exhibit 10.37 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSING AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN SPARK THERAPEUTICS, INC. AND NOVARTIS PHARMA AG January 24, 2018 ActiveUS 166647742v.1 TABLE OF CONTENTS DEFINITIONS; INTERPRETATION 1 1.1Definitions 1 1.2Additional Definitions 11 1.3Interpretatio

LIMITED POWER OF

Exhibit LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all by these presents , that the under s igned hereby makes, constitutes and appoints each of Joseph W.

LIMITED POWER OF

Exhibit LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all by these presents , that the under s igned hereby makes, constitutes and appoints each of Joseph W.

ONCE / Spark Therapeutics, Inc. 8-K (Current Report)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2018 Spark Therapeutics, Inc . (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation

Spark Therapeutics Reports 2017 Financial Results and Recent Business Progress U.S. Food and Drug Administration (FDA) grants breakthrough therapy designation to SPK-8011 for hemophilia A

Exhibit Exhibit 99.1 Spark Therapeutics Reports 2017 Financial Results and Recent Business Progress U.S. Food and Drug Administration (FDA) grants breakthrough therapy designation to SPK-8011 for hemophilia A PHILADELPHIA, Feb. 20, 2018 (GLOBE NEWSWIRE)- Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease , announ

ONCE / Spark Therapeutics, Inc. / FEDERATED INVESTORS INC /PA/ Passive Investment

OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. *) SPARK THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 84652J103 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of th

ONCE / Spark Therapeutics, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

sparktherapeuticsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Spark Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 84652J103 Date of Event Which Requires Filing of this Statement: December 31, 2017 Check the appropri

ONCE / Spark Therapeutics, Inc. / VANGUARD GROUP INC Passive Investment

sparktherapeuticsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Spark Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 84652J103 Date of Event Which Requires Filing of this Statement: December 31, 2017 Check the appropri

Entry into a Material Definitive Agreement

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2018 Spark Therapeutics, Inc . (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation)

ONCE / Spark Therapeutics, Inc. S-8

S-8 1 jan18s-8registrationstatem.htm S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 46-2654405 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 3737 Market Street Sui

ONCE / Spark Therapeutics, Inc. / JP Morgan Chase & Co - NONE Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Spark Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 84652J103 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

ONCE / Spark Therapeutics, Inc. FORM 8-K (Current Report)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2018 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (

LIMITED POWER OF

Exhibit LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all by these presents , that the under s igned hereby makes, constitutes and appoints each of Joseph W.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K 1 perezdirector8-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2018 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdicti

ONCE / Spark Therapeutics, Inc. FORM 8-K (Current Report)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2018 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (

Other Events

8-K 1 luxturnaapproval8-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2017 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Juris

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2017 Spark Therapeutics, Inc . (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation

Financial Statements and Exhibits, Results of Operations and Financial Condition

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2017 Spark Therapeutics, Inc . (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation)

Spark Therapeutics Reports Third Quarter 2017 Financial Results and Recent Business Progress

EX-99.1 2 spark-exhibit991q32017.htm EXHIBIT 99.1 Exhibit 99.1 Spark Therapeutics Reports Third Quarter 2017 Financial Results and Recent Business Progress PHILADELPHIA, Nov. 7, 2017 (GLOBE NEWSWIRE)- Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today financial results for the third quarter of 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR o TRANSITION REP

10-Q 1 spark-201793010xq.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition peri

Spark Therapeutics FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2017 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (C

Spark Therapeutics Announces Pricing of $350.0 Million Public Offering

EX-99.1 Exhibit 99.1 Spark Therapeutics Announces Pricing of $350.0 Million Public Offering PHILADELPHIA, August 3, 2017 ? Spark Therapeutics, Inc. (?Spark?) (NASDAQ: ONCE) announced today the pricing of an underwritten public offering of 4,605,264 shares of its common stock pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchan

SPARK THERAPEUTICS, INC. 4,605,264 Shares of Common Stock, par value $0.001 per share Underwriting Agreement

EX-1.1 Exhibit 1.1 SPARK THERAPEUTICS, INC. 4,605,264 Shares of Common Stock, par value $0.001 per share Underwriting Agreement August 3, 2017 J.P. Morgan Securities LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Spark Therapeutics, Inc., a Delaware corporation (the ?Comp

CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1) Proposed maximum offering price per unit Proposed maximum aggregate offering price(1) Amount of registration fee(2) Common Stock, par value

Final Prospectus Supplement Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No.

You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: 3737 Market Street, Suite 1300 Attn: Investor Relations Philadelphia, PA 19104

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-211993 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement has been filed with the Securities and Exchange Commission and is effective. This prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities

Spark Therapeutics Announces Proposed Public Offering of Common Stock

FWP Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated August 2, 2017 Relating to Prospectus dated June 13, 2016 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2017 Spark Therapeutics, Inc . (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (Commissio

Spark Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Progress Preliminary interim data for SPK-8011 Phase 1/2 dose-escalation clinical trial in hemophilia A show initial human proof-of-concept in three participants In

Exhibit Exhibit 99.1 Spark Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Progress Preliminary interim data for SPK-8011 Phase 1/2 dose-escalation clinical trial in hemophilia A show initial human proof-of-concept in three participants In the two participants at the initial dose, stable factor VIII levels average greater than 12 percent with no spontaneous bleeds In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR o TRANSITION REPORT P

10-Q 1 spark-201763010xq.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fr

Letter Agreement, dated June 6, 2017, amending the License and Option Agreement dated December 2, 2016 between the Registrant and Selecta Biosciences, Inc.

EX-10.1 2 spark-2017630ex101selecta.htm EXHIBIT 10.1 Exhibit 10.1 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. June 6, 2017 Selecta Biosciences, Inc. 480 Arsenal Street, Building One Watertown, MA 02472 Attention: General Counsel Facsimile No.: 617-924-3454 RE: Letter Agreement Regarding Selecta/Spark License an

Spark Therapeutics 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2017 Spark Therapeutics, Inc . (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (C

Spark Therapeutics Receives Rare Pediatric Disease Designation for Investigational LUXTURNA™ (voretigene neparvovec) from FDA

Exhibit Exhibit 99.1 Spark Therapeutics Receives Rare Pediatric Disease Designation for Investigational LUXTURNA? (voretigene neparvovec) from FDA PHILADELPHIA, July 20, 2017 - Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that the Offices of Orphan Products Development and Pediatric Therapeu

Spark Therapeutics’ Biologics License Application for Investigational Voretigene Neparvovec Accepted for Filing by FDA FDA grants Priority Review with Prescription Drug User Fee Act (PDUFA) date of Jan. 12, 2018 LUXTURNATM (voretigene neparvovec) unv

Exhibit Exhibit 99.1 Spark Therapeutics? Biologics License Application for Investigational Voretigene Neparvovec Accepted for Filing by FDA FDA grants Priority Review with Prescription Drug User Fee Act (PDUFA) date of Jan. 12, 2018 LUXTURNA TM (voretigene neparvovec) unveiled as proposed trade name PHILADELPHIA, July 17, 2017 - Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy com

Financial Statements and Exhibits, Other Events

8-K 1 spark-20178kblaacceptance.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2017 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jur

Termination of a Material Definitive Agreement

8-K 1 d364621d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2017 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction o

Spark Therapeutics 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2017 Spark Therapeutics, Inc . (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (Co

Submission of Matters to a Vote of Security Holders

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2017 Spark Therapeutics, Inc . (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (Co

ONCE / Spark Therapeutics, Inc. / Children's Hospital of Philadelphia Foundation - SC 13D/A Activist Investment

CUSIP No. 84652J 103 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 5)* Spark Therapeutics, Inc. (Name of Issuer) Common Stock. $0.001 par value (Title of Class of Securities) 84652J 103 (CUSIP Number) Jeffrey Kahn Executive Vice President and General Counsel The Children’s Hospital of

Spark Therapeutics DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant ? Filed by a Party other than the Registrant: ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy

Spark Therapeutics 10-Q (Quarterly Report)

10-Q 1 spark-201733110xq.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period f

Spark Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Progress Work on U.S. Biologics License Application (BLA) for investigational voretigene neparvovec is complete Interim results from SPK-7001 Phase 1/2 clinical trial

Exhibit Exhibit 99.1 Spark Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Progress Work on U.S. Biologics License Application (BLA) for investigational voretigene neparvovec is complete Interim results from SPK-7001 Phase 1/2 clinical trial in choroideremia reported; continuing enrollment targeting participants at earlier stage of disease PHILADELPHIA, May 9, 2017 (G

Financial Statements and Exhibits, Results of Operations and Financial Condition

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2017 Spark Therapeutics, Inc . (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (Com

Spark Therapeutics DEFA14A

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant x Filed by a Party other than the Registrant: o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy

Spark Therapeutics DEF 14A

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant x Filed by a Party other than the Registrant: o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy

Spark Therapeutics 10-K (Annual Report)

Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36819 Spark Therapeutics, Inc.

License and Option Agreement, dated December 2, 2016 between the Registrant and Selecta Biosciences, Inc.

Exhibit 10.32 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AND OPTION AGREEMENT by and between SPARK THERAPEUTICS, INC. and SELECTA BIOSCIENCES, INC. December 2, 2016 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INTERPRETATION1 1.1Definitions 1 1.2Additional Definitions 13 1.3Interpretation 14 ARTICL

Name Jurisdiction of Incorporation Spark Therapeutics, Inc. Delaware Spark Therapeutics International Holdings, Inc. Delaware Spark Therapeutics International Holdings, Inc. Delaware Spark Therapeutics Ireland Limited Ireland Spark Therapeutics Engla

Exhibit 21.1 The following is a list of subsidiaries of the Company as of December 31, 2016: Name Jurisdiction of Incorporation Spark Therapeutics, Inc. Delaware Spark Therapeutics International Holdings, Inc. Delaware Spark Therapeutics International Holdings, Inc. Delaware Spark Therapeutics Ireland Limited Ireland Spark Therapeutics England Limited England

Spark Therapeutics Reports 2016 Financial Results and Business Highlights Investigational voretigene neparvovec Biologics License Application (BLA) on track for completion in early 2017 Three additional clinical-stage programs continue to advance, in

Exhibit Exhibit 99.1 Spark Therapeutics Reports 2016 Financial Results and Business Highlights Investigational voretigene neparvovec Biologics License Application (BLA) on track for completion in early 2017 Three additional clinical-stage programs continue to advance, including initiation of hemophilia A Phase 1/2 trial PHILADELPHIA, Feb. 22, 2017 (Globe Newswire)- Spark Therapeutics (NASDAQ: ONCE

Spark Therapeutics 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Febraury 22, 2017 Spark Therapeutics, Inc . (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation

Spark Therapeutics 3G (Passive Acquisition of More Than 5% of Shares)

sparktherapeuticsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: Spark Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 84652J103 Date of Event Which Requires Filing of this Statement: December 31, 2016 Check the appropri

ONCE / Spark Therapeutics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - ONCE AS OF 01/31/2017 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) SPARK THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 84652J103 (CUSIP Number) January 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedul

Spark Therapeutics S-8

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 46-2654405 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 3737 Market Street Suite 1300 Philadelphia, Pennsylvan

ONCE / Spark Therapeutics, Inc. / Sofinnova Venture Partners VIII, L.P. - SC 13D/A Activist Investment

SC 13D/A 1 v455641sc13d-a.htm SC 13D/A CUSIP NO. 84652J103 13D Page 1 of 16 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Spark Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of

ONCE / Spark Therapeutics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - ONCE AS OF 11/30/2016 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) SPARK THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 84652J103 (CUSIP Number) November 30, 2016 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedu

Spark Therapeutics 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2016 Spark Therapeutics, Inc . (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation)

Spark Therapeutics 8-K (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2016 Spark Therapeutics, Inc . (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation)

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Exhibit LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Joseph W.

Spark Therapeutics 10-Q (Quarterly Report)

Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36819 Spark Therapeutics, Inc.

Spark Therapeutics Reports Third Quarter 2016 Financial Results and Recent Business Highlights Completion of Biologics Licensing Application (BLA) submission for investigational candidate voretigene neparvovec on track for early 2017 Company makes pr

EX-99.1 2 spark-exhibit991q32016.htm EXHIBIT 99.1 Exhibit 99.1 Spark Therapeutics Reports Third Quarter 2016 Financial Results and Recent Business Highlights Completion of Biologics Licensing Application (BLA) submission for investigational candidate voretigene neparvovec on track for early 2017 Company makes progress across multiple programs, including its hemophilia franchise PHILADELPHIA, Nov.

Spark Therapeutics 8-K EARNINGS RELEASE (Current Report/Significant Event)

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2016 Spark Therapeutics, Inc . (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation)

ONCE / Spark Therapeutics, Inc. / Children's Hospital of Philadelphia Foundation - SC 13D/A Activist Investment

CUSIP No. 84652J 103 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 4)* Spark Therapeutics, Inc. (Name of Issuer) Common Stock. $0.001 par value (Title of Class of Securities) 84652J 103 (CUSIP Number) Jeffrey Kahn Executive Vice President and General Counsel The Children’s Hospital of

Spark Therapeutics 10-Q (Quarterly Report)

Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36819 Spark Therapeutics, Inc.

Form of Employment Agreement for Executive Officer

Exhibit Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is made as of , 2016, by and between Spark Therapeutics, Inc. (the ?Company?), and , (the ?Executive?) (together, the ?Parties?). RECITALS Whereas, the Company desires to employ the Executive as its ; and Whereas, the Executive has agreed to accept such employment on the terms and conditions set forth in this Agr

Amendment No. 1, dated June 9, 2016, to the License Agreement dated December 6, 2014 between the Registrant and Pfizer

Exhibit Confidential Materials omitted and filed separately with the Securities and Exchange Commission.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2016 Spark Therapeutics, Inc . (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (Commissi

Spark Therapeutics Announces New Positive Data from Continuation of Phase 3 Trial of Voretigene Neparvovec Of the nine crossover subjects, eight responders demonstrated the maximum improvement measurable on the primary endpoint at one year 27 of 29,

Exhibit Exhibit 99.2 Spark Therapeutics Announces New Positive Data from Continuation of Phase 3 Trial of Voretigene Neparvovec Of the nine crossover subjects, eight responders demonstrated the maximum improvement measurable on the primary endpoint at one year 27 of 29, or 93%, of Phase 3 subjects that received voretigene neparvovec demonstrated a gain in functional vision at one year Follow-up da

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2016 Spark Therapeutics, Inc . (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (Commissi

Spark Therapeutics Reports Second Quarter 2016 Financial Results and Recent Business Highlights Updated timing of the completed BLA submission for voretigene neparvovec Earlier today, released additional positive data from the pivotal Phase 3 trial o

Exhibit Exhibit 99.1 Spark Therapeutics Reports Second Quarter 2016 Financial Results and Recent Business Highlights Updated timing of the completed BLA submission for voretigene neparvovec Earlier today, released additional positive data from the pivotal Phase 3 trial of voretigene neparvovec Reported positive preliminary safety and efficacy from the Phase 1/2 clinical trial of SPK-9001 in hemoph

Spark Therapeutics Announces New Positive Data from Continuation of Phase 3 Trial of Voretigene Neparvovec Of the nine crossover subjects, eight responders demonstrated the maximum improvement measurable on the primary endpoint at one year 27 of 29,

Exhibit Exhibit 99.2 Spark Therapeutics Announces New Positive Data from Continuation of Phase 3 Trial of Voretigene Neparvovec Of the nine crossover subjects, eight responders demonstrated the maximum improvement measurable on the primary endpoint at one year 27 of 29, or 93%, of Phase 3 subjects that received voretigene neparvovec demonstrated a gain in functional vision at one year Follow-up da

SPARK THERAPEUTICS, INC. CONFIDENTIALITY AGREEMENT August 26, 2015

EXHIBIT 2 SPARK THERAPEUTICS, INC. CONFIDENTIALITY AGREEMENT August 26, 2015 The Children’s Hospital of Philadelphia 34th Street and Civic Center Boulevard Philadelphia, PA 19104 In connection with your status as holder of securities in Spark Therapeutics, Inc. (the “Company”), and as further contemplated by Section 3.2 of that certain Investors’ Rights Agreement, dated May 23, 2014 (the “Investor

ONCE / Spark Therapeutics, Inc. / Children's Hospital of Philadelphia Foundation - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 3)* Spark Therapeutics, Inc. (Name of Issuer) Common Stock. $0.001 par value (Title of Class of Securities) 84652J 103 (CUSIP Number) Jeffrey Kahn Executive Vice President and General Counsel The Children’s Hospital of Philadelphia Foundation

Spark Therapeutics ESP

CORRESP SPARK THERAPEUTICS, INC. 3737 MARKET STREET, SUITE 1300 PHILADELPHIA, PENNSYLVANIA 19104 June 20, 2016 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Spark Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-211993 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under

CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1) Proposed maximum offering price per unit Proposed maximum aggregate offering price(1) Amount of registration fee(2) Common Stock, par value

Final Prospectus Supplement Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No.

Spark Therapeutics FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2016 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (Co

Spark Therapeutics Announces Pricing of Public Offering

EX-99.1 Exhibit 99.1 Spark Therapeutics Announces Pricing of Public Offering PHILADELPHIA, June 14, 2016? Spark Therapeutics, Inc. (?Spark?) (NASDAQ: ONCE) announced today the pricing of an underwritten public offering of 3,500,000 shares of its common stock pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission at

SPARK THERAPEUTICS, INC. 3,500,000 Shares of Common Stock, par value $0.001 per share Underwriting Agreement

EX-1.1 Exhibit 1.1 SPARK THERAPEUTICS, INC. 3,500,000 Shares of Common Stock, par value $0.001 per share Underwriting Agreement June 14, 2016 J.P. Morgan Securities LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Spark Therapeutics, Inc., a Delaware corporation (the ?Compa

You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: 3737 Market Street, Suite 1300 Attn: Investor Relations Philadelphia, PA 19104

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-211993 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement has been filed with the Securities and Exchange Commission and is effective. This prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these secu

Spark Therapeutics Announces Launch of Public Offering

FWP Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated June 13, 2016 Relating to Prospectus dated June 13, 2016 Registration No.

Form of Senior Note (FACE OF SECURITY)

EX-4.6 Exhibit 4.6 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE

Form of Subordinated Note (FACE OF SECURITY)

EX-4.7 Exhibit 4.7 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER N

CALCULATION OF CONSOLIDATED RATIOS OF EARNINGS TO FIXED CHARGES AND RATIOS OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS Three months ended March 31, 2016 Year ended December 31, 2015 Year ended December 31, 2014 March 13, 2013

EX-12.1 Exhibit 12.1 CALCULATION OF CONSOLIDATED RATIOS OF EARNINGS TO FIXED CHARGES AND RATIOS OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS Three months ended March 31, 2016 Year ended December 31, 2015 Year ended December 31, 2014 March 13, 2013 (inception) through December 31, 2013 (Dollars in thousands) Pre-tax loss $ (25,577 ) $ (47,126 ) $ (24,325 ) $ (57,278 ) Add: Fi

SPARK THERAPEUTICS, INC. Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable

EX-4.4 Exhibit 4.4 SPARK THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 31

SPARK THERAPEUTICS, INC. Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inappli

EX-4.5 Exhibit 4.5 SPARK THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4

As filed with the Securities and Exchange Commission on June 13, 2016

Form S-3ASR Table of Contents As filed with the Securities and Exchange Commission on June 13, 2016 Registration No.

Spark Therapeutics FORM S-3

Form S-3 Table of Contents As filed with the Securities and Exchange Commission on June 3, 2016 Registration No.

Submission of Matters to a Vote of Security Holders

Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2016 Spark Therapeutics, Inc . (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (Co

Other Events

8-K 1 spark-51916pfizer.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2016 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction

Spark Therapeutics 10-Q (Quarterly Report)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36819 Spark Therapeutics, Inc.

Spark Therapeutics Reports First Quarter 2016 Financial Results and Recent Business Highlights Company makes progress across multiple programs Appoints Daniel R. Faga as Chief Business Officer

Exhibit Exhibit 99.1 Spark Therapeutics Reports First Quarter 2016 Financial Results and Recent Business Highlights Company makes progress across multiple programs Appoints Daniel R. Faga as Chief Business Officer PHILADELPHIA, Penn., May 4, 2016 ? Spark Therapeutics (NASDAQ: ONCE) today announced financial results for the quarter ended March 31, 2016 and updated investors on its progress. ?During

Spark Therapeutics 8-K Q1 EARNINGS RELEASE (Current Report/Significant Event)

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2016 Spark Therapeutics, Inc . (Exact Name of Registrant as Specified in its Charter) Delaware 001-36819 46-2654405 (State or Other Jurisdiction of Incorporation) (Commissi

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all by these presents,that the undersigned hereby makes, constitutes and appoints each of Daniel R.

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Exhibit LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Joseph W.

Spark Therapeutics DEF 14A

DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant x Filed by a Party other than the Registrant: o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy

Spark Therapeutics S-8

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Spark Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 46-2654405 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 3737 Market Street Suite 1300 Philadelphia, Pennsylvania 19104

Spark Therapeutics 10-K (Annual Report)

10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36819 Spark Therapeutics, Inc.

Amendment, dated January 5, 2016 to the Employment Agreement between the Registrant and Jeffrey D. Marrazzo

Exhibit 10.32 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (the “Amendment”) is made as of January 5, 2016, by and between Spark Therapeutics, Inc., a Delaware corporation with its principal place of business at 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (the “Company”), and Jeffrey D. Marrazzo (the “Executive”). WITNESSETH: WHEREAS, the Company and the Executive have entered into

Amendment dated March 10, 2016, to the License Agreement dated November 23, 2015 between the Registrant and The Children's Hospital of Philadelphia

Exhibit 10.36 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AGREEMENT AMENDMENT This Amendment (the "Amendment"), with an effective date of November 23, 2015 (the "Effective Date") serves as a modification to the November 23, 2015 License Agreement made by and between Spark Therapeutics, Inc., a Delaware

Amended and Restated Patent License Agreement dated December 31, 2015, between the Registrant and The Trustees of the University of Pennsylvania

Exhibit 10.31 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. Final Execution Copy University of Pennsylvania Amended and Restated Patent License Agreement This Amended and Restated Patent License Agreement (this “Agreement”) amends and restates that certain Patent License Agreement (the “Original Agreement”) execu